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Abstract
Purpose Intraoperative localisation and preservation of parathyroid glands improves outcomes following thyroid and parathyroid
surgery. This can be facilitated by fluorescent imaging and methylene blue; a fluorophore is thought to be taken up avidly by
parathyroid glands. This preliminary study aims to identify the optimum dose of methylene blue (MB), fluorescent patterns of
thyroid and parathyroid glands and develop a protocol for the use of intravenous MB emitted fluorescence to enable parathyroid
identification.
Methods This is a phase 1b, interventional study (NCT02089542) involving 41 patients undergoing thyroid and/or parathyroid
surgery. After exposure of the thyroid and/or parathyroid gland(s), intravenous boluses of between 0.05 and 0.5 mg/kg of MB
were injected. Fluobeam® (a hand held fluorescence real-time imager) was used to record fluorescence from the operating field
prior and up to 10 min following administration.
Results The optimum dose of MB to visualise thyroid and parathyroid glands was 0.4 mg/kg body weight. The median time to
onset of fluorescence was 23 and 22 s and the median time to peak fluorescence was 41.5 and 40 s, respectively. The peak
fluorescence for thyroid and parathyroid glands compared to muscle were 2.6 and 4.3, respectively. Parathyroid auto-
fluorescence prior to methylene blue injection was commonly observed.
Conclusions A clinical protocol for detection of fluorescence from MB during thyroid and parathyroid surgery is presented.
Parathyroids (especially enlarged glands) fluoresce more intensely than thyroid glands. Auto-fluorescence may aid parathyroid
detection, but MB fluorescence is needed to demonstrate viability.
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Introduction
Transient and long-term post-surgical hypoparathyroidism
due to inadvertent removal, damage or devascularisation of
parathyroid glands remains a common problem [1–4].
Accurate identification and differentiation between normal
and enlarged parathyroid glands is essential for a good
outcome.
Parathyroid glands can have a varied position and their
small size and soft consistency increases the risk of inaccurate
identification and damage at surgery. These glands may also
be mistaken for other soft tissues such as lymph nodes or
thyroid nodules, or vice versa.
Near-infrared fluorescence (NIRF) is one of several novel
technologies that may be useful in early identification and
preservation of parathyroid glands during surgery.
Fluorophores re-emit light of a higher wavelength when ex-
cited by a light source. Some emit light outside of the visible
spectrum in the near infra-red region (700–900 nm) [5]. NIRF
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has been used in surgery to aid real-time intraoperative visu-
alisation of tissues and differentiate between tissue types
[6–10] including sentinel lymph node mapping [6, 10–12].
Fluorophores that are currently available for clinical use in-
clude methylene blue (MB), indocyanine green (ICG) and 5-
aminolevulinic acid (5-ALA). Intraoperative use of NIRF ex-
ploits the routes of metabolism and clearance of these agents
in the body. ICG, excreted by the liver, is present in bile. This
has been used to image bile ducts and liver cancers [8, 13–17].
MB, excreted via the kidneys, allows imaging of the ureters
[7, 18]. Studies in neurosurgery have found that 5-ALA al-
lows intraoperative assessment of tumours including menin-
gioma [19].
Methylene blue is likely to be favourable for use in thyroid
and/or parathyroid surgery as it is taken up readily by endo-
crine tissues [20, 21]. MB has traditionally been used intrave-
nously in high doses (3–7.5 mg/kg) to aid naked eye identifi-
cation of enlarged parathyroid glands by discolouring the
gland blue. This method is thought to be very sensitive [22].
However, high-dose MB has many disadvantages. The oper-
ative field may be discoloured by blue dye; the staining may
not be visualised through overlying tissue or fascia; there may
be significant discolouration of the patient’s skin and urine
and patients may suffer severe allergic reaction to the dye,
but this is rare. At these high doses, MB also exerts neurotoxic
effects, especially when used in conjunction with serotonin re-
uptake inhibitors (SSRIs), adding significant morbidity to an
otherwise relatively safe procedure [22, 23].
MB emits light in the near-infrared range (~ 700 nm). As
near-infrared (NIR) light is invisible to the naked eye, the dye
does not stain the operating field. Its presence is detected by a
camera and is projected to a screen for visualisation. An addi-
tional advantage is that NIR radiation penetrates tissue better
than visible light. The Fluobeam® 700 (Fluoptics, Grenoble,
France) is a portable NIRF imaging system comprising of a
control box linked to a camera head. The instrument head
contains a class 1 laser (wavelength 680 nm), white light
emitting diodes (LED) and a charge-coupled device camera.
A high-band pass filter ensures that only fluorescent light over
700 nm is collected. The control box is linked to a laptop
where real-time still and video images are displayed on screen
and recorded.
We have previously investigated the use of MB and this
imaging system in a rabbit model and showed that both thy-
roid and parathyroid glands fluoresced at low doses (0.025–
3 mg/kg) of MB; the parathyroid glands showed a lower in-
tensity of fluorescence with faster washout when compared to
the thyroid gland [24].
A Phase Ia human study evaluated the feasibility of using
NIRF imaging in the detection of parathyroid tissue and the
patterns of fluorescent staining during parathyroidectomy
[25]. This study showed that MB fluorescence can be demon-
strated during surgery and there are differences in
fluorescence between thyroid, parathyroid and other soft tis-
sue structures. Although MB fluorescence from human thy-
roid and parathyroid tissue has been reported recently [26, 27],
a systematic evaluation of dose response and temporal chang-
es in fluorescence has not been performed.
The aim of the current study was to develop a protocol for
the use of Fluobeam® 700 in combination with intravenous
MB, for the detection of parathyroid tissue with differentiation
from adjacent soft tissue, during thyroid and parathyroid sur-
gery. The objectives were to identify the optimum dose of
intravenous MB and time to peak fluorescence of normal
and abnormal thyroid and parathyroid glands and to determine
differences in patterns (onset, intensity and duration) of fluo-
rescent staining between the various soft tissues of interest in
the neck.
Methods
This is an interventional study, without a control arm. Two
groups of patients were included—patients with primary hy-
perparathyroidism (PHPT) undergoing parathyroidectomy
(bilateral neck exploration/targeted parathyroidectomy) and
patients undergoing thyroid resection (hemithyroidectomy/to-
tal thyroidectomy).
At thyroid and/or parathyroid surgery under general anaes-
thesia, the intervention was paused after exposure of the thy-
roid gland and at least one parathyroid gland to assess fluo-
rescence. Accurate identification of the parathyroid gland re-
lied on the surgeon’s judgement based on the appearance and
location of the gland. In patients undergoing parathyroid sur-
gery, the abnormal gland was identified. If the patient was
undergoing a bilateral procedure, only one side of the neck
was included in the recordings and assessments. The study
could only proceed after at least one parathyroid gland was
identified with confidence by the surgeon. At this stage, the
Fluobeam® 700 camera in a sterile, transparent cover and
connected to a laptop computer was held at a working distance
of around 20 cm from the surgical field. The ambient room
light was dimmed to a level similar to that used during lapa-
roscopic surgery and the camera set at an exposure time of
83 ms. Intravenous methylene blue was then administered at a
pre-determined dose based on results from previous partici-
pants in the study. For the first patient, a dose of 0.05 mg/kg
body weight of MB was administered based on extrapolation
from the previous animal experiment [24]. A sequence of
images was recorded with a fixed interval time of 1 s between
images. Recording was started before methylene blue was
infused and continued for 10 min in the majority of patients.
Continuous ECG and saturation monitoring was used in all
patients. Blood pressure was monitored at 5-min intervals
throughout the operation.
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The study was divided into three stages—‘training’, ‘test-
ing’ and ‘final’. The aim of the training stage was to estimate
the optimal dose of MB, the duration of observation and to
develop a working protocol. The dose of MB was refined in
the testing stage before moving onto the final stage where the
agreed protocol was tested. In the training and testing stages,
MB doses starting at 0.05 mg/kg were administered and in-
creased in increments of 0.05 mg/kg up to a maximum of
0.5 mg/kg in subsequent patients. The incremental change in
dose depended on the results obtained from previous patients
in the trial and the nature of the surgery (thyroid vs parathy-
roid) and was decided upon by the primary investigators (SH
and SPB).
Images captured were analysed using ImageJ software [28].
Fluorescence intensity readings were taken from the thyroid
gland, parathyroid gland, soft tissue (muscle or subcutaneous
tissue) and surgical drapes. The mean grey scale measurement
from the defined area was plotted against time. Ratios were
calculated of the thyroid and parathyroid glands compared to
soft tissue and the drapes and also plotted against time.
There are no formal statistical grounds (e.g. precision or
power) on which an informed decision could be made regard-
ing sample size calculations. A sample size of 50 (25 of each
procedure) was selected on pragmatic grounds, keeping in
mind the design of the protocol.
Onset of fluorescence and peak fluorescence readings were
taken from the first 120 s after administration of MB. This
captured the onset and first peak of fluorescence in all cases.
As recording continued past 5 min, there was a significant
increase in artefact from repositioning of hands and instru-
ments and camera movement. Further peaks after this time
were therefore disregarded. Analyses of fluorescent intensity
were limited to the first 120 s of recording in patients given the
final dose of 0.4 mg/kg MB. The first few seconds of record-
ing, prior to administration of MB, was used to evaluate para-
thyroid auto-fluorescence.
Data analyses were primarily descriptive. The time to peak
fluorescence of the thyroid and parathyroid glands and the
fluorescent ratios were compared using the Wilcoxon signed
rank test.
The study was approved by the Medicines and Healthcare
Regulatory Agency (MHRA) (Reference number: 21304/
0252/001-0001) and the Regional Research Ethics
Committee (REC) (Reference number: 14/NW/0270). The
study protocol was registered with ClinicalTrials.gov [29].
All patients included in the study were fully informed and
gave written consent.
Results
A total of 101 patients who were due to undergo thyroid and/
or parathyroid surgery were screened for eligibility,
approached for participation and given study information leaf-
lets. A second meeting was planned with all patients to con-
firm eligibility and consent. The flow of patients from initial
screening to inclusion in the study is shown in Fig. 1.
Of the 42 patients (36 female, 6 male), 32 underwent sur-
gery for thyroid pathology and 10 for primary hyperparathy-
roidism. The median age (range) of participants was 49 (20–
85). One patient was withdrawn prior to administration ofMB
as a decision was made not to interrupt the surgery due to
anaesthetic difficulties that were encountered intraoperatively
and is therefore not included in the study. Twenty-one patients
were included in the training stage, 14 in the testing stage and
6 in the final stage. The training stage was used to find the
approximate dose of MB that would be required by systemat-
ically increasing the dose by 0.05 mg/kg until fluorescence
was reliably demonstrable in the tissues. The testing phase
narrowed down the dose from a narrow range (0.3–0.5 mg/
kg) to a single dose that was taken forward to the final stage
(0.4 mg/kg). Two patients’ results were excluded as the laser
was inadvertently switched off during recording in one and
bright ambient light adversely affected detection of fluores-
cence in another.
There was a predictable, transient and spurious fall in oxy-
gen saturation (pseudohypoxia) within the first minute of ad-
ministration of MB, which recovered completely in all pa-
tients within 30 s. Oxygen saturations were shown to fall
briefly to as low as 65%. All other hemodynamic parameters
were stable at this time. This fall in saturation is due to an
artefactual change in light absorbance as the dye in plasma
interferes with photometric measurement of blood oxygen
saturation [30, 31]. No patients had significant hypotension
or ECG changes in relation to the administration of MB. No
visible staining was observed of the glands or the rest of the
surgical field. Postoperatively, some patients commented on a
transient discolouration of urine but no other side effects were
noted.
The parathyroid glands were often noted to be fluorescent
and distinct from surrounding soft tissue prior to administra-
tion of methylene blue (auto-fluorescence). The mean differ-
ence in relative intensity between the PG and thyroid gland
was +1.3 (n = 14) in the 10 s prior to MB administration in
patients administered 0.4 mg/kg. Fluorescence was detected
from the thyroid and PGs at doses as low as 0.05 mg/kg.
However, at this dose, fluorescence was short-lived (around
8 s) and therefore unlikely to be useful in clinical practice.
Enlarged parathyroid glands (adenomatous or hyperplastic
tissue in the context of primary hyperparathyroidism) showed
increased fluorescence compared to normal glands. In one
patient where an abnormal and normal parathyroid gland were
both in view; at a dose of 0.1 mg/kg MB, the enlarged para-
thyroid gland demonstrated a peak fluorescence parathyroid:
muscle ratio of 4.5 compared to 2.1 for the normal appearing
gland. With increasing dose of MB, enlarged parathyroid
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glands showed intense fluorescence compared to surrounding
tissues and in comparison to thyroid and normal PGs. Eleven
PGs thought to be abnormal by the surgeon were sent for
histology. All of these were shown on histology to be parathy-
roid tissue. Ten of these glands were abnormal (8 adenoma, 2
hyperplastic) and one was a normal parathyroid.
At the end of the testing phase, a dose of 0.4 mg/kg was
adopted as the optimum dose (Figs. 2 and 3). At this dose,
fluorescence from normal PGs was deemed to be reliable. A
total of 15 patients received 0.4 mg/kg of MB (thyroid = 12,
parathyroid = 3). The median of the times to onset of fluores-
cence, time to peak fluorescence, gland to ‘drape’ ratios and
gland to muscle ratios at this dose are shown in Table 1.
At this dose, the thyroid and PGs show a similar time to
onset of fluorescence (p = 0.109) regardless of pathology. The
time to peak fluorescence was 41.5 s (28–103) and 40s (26–
88) for thyroid and parathyroid glands respectively and this
was not significantly different (p = 0.859). PGs fluoresce more
intensely than the thyroid when comparing either the gland to
drape (p = 0.019) or gland to muscle ratios (p = 0.013).
Abnormal parathyroid glands appear to fluoresce brighter than
normal PGs, but the numbers within these sub groups are too
small to test for statistical significance.
Discussion
To our knowledge, this is the first human, phase I intraoperative
dose response study of any fluorescent agent in surgical litera-
ture. The dose of 0.4 mg/kg MB appears to be the optimum
level at which both thyroid and PGs reliably fluoresce for a
clinically useful period of time. Increasing the dose does not
improve the quality of images. At this dose, PGs appeared to
fluoresce brighter than the adjacent thyroid tissue in the major-
ity of patients. PG adenomas showed significantly brighter
fluorescence compared to normal glands at the same dose.
Parathyroid glands have been shown to auto-fluoresce in
the near-infrared spectrum. Two other studies evaluating para-
thyroid auto-fluorescence at wavelengths 750 nm [32] and
785 nm [33, 34] have shown that the parathyroid fluoresces
between 2 and 11 times more than the thyroid or other neck
structures [32–34]. The mechanism behind parathyroid auto-
fluorescence is not yet understood and the fluorescence ap-
pears to be independent of pathology and gland viability [32,
35]. This study has demonstrated auto-fluorescence at excita-
tion wavelength of 680 nm and this has not previously been
observed. Although auto-fluorescence may aid intraoperative
parathyroid identification, a further assessment of viability is
needed to help make the decision for auto-transplantation as
auto-fluorescence appears to be independent of perfusion.
This is highlighted by an example in this study where there
were concerns about viability in one parathyroid. Here, the PG
was visible with use of the Fluobeam® 700 prior to the bolus
of MB. The PG did not show any change in fluorescence after
the bolus for up to 7 min after injection; which was not in
keeping with other glands that were deemed to be viable.
The demonstration of auto-fluorescence at 680 nm that is also
compatible with MB fluorescence is of significance because
the same device/technology can be used to both screen for the
presence of parathyroid glands and also determine their via-
bility after MB administration (Fig. 4).
Alternative imaging systems such as FLARE™ and Mini-
FLARE™ have been used in some studies to assess MB fluo-
rescence of parathyroid adenomas [26, 27]. A fixed dose of
101 paents pre-
screened
71 paents reviewed for 
consent
41 paents parcipated
1 paent was withdrawn
2 declined
28 unable to meet 
researcher again
22 not eligible
7 declined consent
2 paents excluded
Fig. 1 Recruitment flow chart
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0.5 mg/kg was used in all patients included in the studies,
which concluded that parathyroid adenomas could be local-
ised intraoperatively using this method and that normal PGs
could occasionally be seen [26]. However, the basis of this
fixed dose is not clear and no dose response assessments were
included in the published reports.
Our study has shown that both normal and abnormal PGs
can be identified at doses as low as 0.4 mg/kg (around 7.5–
17.5 times lower than doses previously used for macroscopic
blue staining). At this dose, the viability of a parathyroid gland
can be confirmed and it may be possible to differentiate para-
thyroid adenoma from normal glands during a neck explora-
tion. MB fluorescence can also be used to differentiate be-
tween PG and surrounding soft tissue such as lobules of
brown fat or lymph nodes. Although the thyroid gland fluo-
resces following MB administration, the differences in auto-
fluorescence along with MB fluorescence patterns assist in
distinguishing parathyroids from thyroid tissue.
This study shows the potential for parathyroid auto-
fluorescence at 680 nm to be used as a screening method
for early parathyroid identification and MB fluorescence
following intravenous administration for confirmation of
parathyroid glands and assessment of its viability. The tech-
nology may be of help in a number of different scenarios—
early parathyroid identification to enable preservation of
normal glands during thyroidectomy; assessment of viabil-
ity of parathyroid glands at the end of thyroidectomy to
determine the need for auto-transplantation; and early iden-
tification of enlarged parathyroid glands in parathyroid sur-
gery. This has in turn the potential to improve outcomes of
thyroid and parathyroid surgery. As the onset of fluores-
cence from the tissues is seen within seconds of MB admin-
istration, the presented method enables a rapid assessment
of viability without extensive preparation.
There are a number of factors that affect the quantitative
assessment of fluorescent intensity during the operation.
50
100
150
200
250
300
1 61 121 181 241 301 361 421 481 541 60
F
l
u
o
r
e
s
c
e
n
c
e
 
M
e
a
n
 
(
g
r
e
y
s
c
a
l
e
/
m
s
)
Time (S)
0.1mg/kg
0
50
100
150
200
250
300
1 61 121 181 241 301 361 421 481 541 601
F
l
u
o
r
e
s
c
e
n
c
e
 
M
e
a
n
 
(
g
r
e
y
s
c
a
l
e
/
m
s
)
Time (S)
0.2mg/kg
0
50
100
150
200
250
300
1 61 121 181 241 301 361 421 481 541 601
F
l
u
o
r
e
s
c
e
n
c
e
 
M
e
a
n
 
(
g
r
e
y
s
c
a
l
e
/
m
s
)
Time (S)
0.35mg/kg
0
50
100
150
200
250
300
1 61 121 181 241 301 361 421 481 541 601
F
l
u
o
r
e
s
c
e
n
c
e
 
M
e
a
n
 
(
g
r
e
y
s
c
a
l
e
/
m
s
)
Time (S)
0.4mg/kg
Parathyroid Thyroid
Fig. 2 Mean fluorescence of normal parathyroid and abnormal thyroid glands over at four different concentrations of MB in individuals with Graves’
disease
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These include the distance of the camera from the tissues due
to operator use or depth of the surgical field, the position of the
gland within the field of view and degradation of the image
due to the original sterile cover. Adjusting for all these factors
and keeping all extraneous factors constant is difficult in clin-
ical practice. However, despite these extraneous influences, an
objective assessment of fluorescent intensity using ImageJ
enabled comparison of fluorescence between soft tissues at
different doses and over time. This has resulted in the devel-
opment of a clinical protocol that can be used in a pragmatic
manner in the clinical setting. For the purpose of the experi-
ments, both the thyroid and PG remained in a fixed field of
view throughout the recording. This may affect the fluores-
cence detected by the camera from the more peripheral areas
of the field of view compared to the centre as the laser exci-
tation is highest in the centre. In practice, surgeons may use
the camera in a less static manner and therefore the centre of
the field of view may change as different areas of the neck are
investigated. ImageJ was used post-acquisition as a method of
quantifying the fluorescence detected from the images obtain-
ed. A mean greyscale measurement of the pixels within a
chosen area is a representation of fluorescence. The areas of
interest were determined by free-hand selection. The images
were occasionally degraded by surgical instruments or hands
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Fig. 3 Mean fluorescence of abnormal parathyroid and normal thyroid glands over time at four different concentrations of MB in individuals with
primary hyperparathyroidism
Table 1 Fluorescent patterns of thyroid and parathyroid glands at dose of 0.4 mg/kg body weight
Median time in seconds to
onset of fluorescence (range)
Median time in seconds to
peak fluorescence (range)
Median peak gland to
drape ratio (range)
Median peak gland to
muscle ratio (range)
Parathyroid gland (n = 15) 22.0 (13–33) 40.0 (26–88) 17.8 (6.7–54.8) 4.3 (1.7–6.8)
Thyroid gland (n = 14) 23.0 (12–34) 41.5 (27–103) 10.4 (5.7–29.7) 2.6 (1.1–5.1)
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entering the field of view and obscuring all or part of a gland.
In this case, an area was selected which best represented the
gland. It was also noted that over the period of 10 min there
was operator fatigue and movement of the tissues of interest
outside the field of view. During the repositioning of the in-
struments or surgeon’s fingers used for retraction of the thy-
roid, there were changes in fluorescence due to changes in
exposure, movement from the centre of the field of view or
changes in blood supply due to pressure on adjacent vascula-
ture. Whilst attempts were made to take the reading from
muscle, some of these readings may have been at least in part
from adjacent subcutaneous soft tissue as it was difficult to
always ensure that the strap muscles were in view during
recording.
TheMBwas injected via a tubing connected to a peripheral
cannula. The size of this tubing varied in diameter, depending
on the anaesthetist’s preference. It was noted that despite
flushing of the tubing after administration of MB, occasional-
ly, MBwas left in the tubing. It is therefore recommended that
MB is administered via a fine tube or connector to the periph-
eral cannula.
In conclusion, parathyroid glands can be identified intraop-
eratively using NIR imaging following administration of in-
travenous methylene blue at doses as low as 0.4 mg/kg. PG
fluorescence is observed within 60 s of administration and
PGs fluoresce more intensely than the thyroid tissue.
Enlarged parathyroid glands may be distinguished from nor-
mal glands based on the fluorescence intensity. This method
has potential in enabling early and accurate identification of
parathyroid glands and determining gland viability, thereby
improving outcomes in thyroid and parathyroid surgery. A
phase II study of this protocol to evaluate clinical outcomes
such as post thyroidectomy hypoparathyroidism is now
required.
Acknowledgements Emma E Collins1, Peter P Truran1, Chern B Lim1,
Barnard J Harrison1, Mireille C Berthoud2
1. Directorate of General Surgery, Sheffield Teaching Hospitals NHS
Foundation Trust
2. Directorate of Anaesthesia, Sheffield Teaching Hospitals NHS
Foundation Trust Clinical Research Facility (CRF) and operative ser-
vices, Sheffield Teaching Hospitals NHS Foundation Trust
Compliance with ethical standards
Conflict of interest Authors SLHillary and SPBalasubramanian declare
that study equipment was on loan from Fluoptics. Author S Guillermet
declares that she is employed by Fluoptics. Author N Brown declares that
she has no conflict of interest.
Ethical approval All procedures performed in studies involving human
participants were in accordance with the ethical standards of the institu-
tional and/or national research committee and with the 1964 Helsinki
declaration and its later amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all individual
participants included in the study.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Antakia R, Edafe O, Uttley L, Balasubramanian SP (2015)
Effectiveness of preventative and other surgical measures on hypo-
calcemia following bilateral thyroid surgery: a systematic review
and meta-analysis. Thyroid 25(1):95–106. https://doi.org/10.1089/
thy.2014.0101
2. Chadwick D, Kinsman R, Walton P (2012) The British
Association of Endocrine and Thyroid Surgeon Fourth
National Audit. Dendrite Clinical Systems Ltd, Henley-on-
Thames. Available from: http://www.baets.org.uk/Pages/4th%
20National%20Audit.pdf
3. Steen S, Rabeler B, Fisher T, Arnold D (2009) Predictive
factors for early postoperative hypocalcemia after surgery for
primary hyperparathyroidism. Proc (Bayl Univ Med Cent)
22(2):124–127
4. Basheeth N, O'Cathain E, O'Leary G, Sheahan P (2014)
Hypocalcemia after total laryngectomy: incidence and risk factors.
Laryngoscope 124(5):1128–1133. https://doi.org/10.1002/lary.
24429
5. Schaafsma BE, Mieog JS, Hutteman M, van der Vorst JR, Kuppen
PJ, Lowik CWet al (2011) The clinical use of indocyanine green as
a near-infrared fluorescent contrast agent for image-guided
Fig. 4 Patient with thyroid nodule undergoing right hemithyroidectomy.
a Colour photograph of surgical field. Thyroid retracted medially by
surgeon’s fingers. Normal superior PG identified dotted circle. b NIRF
image prior to injection of MB showing parathyroid auto-fluorescence
(dotted circle). c NIRF image at peak parathyroid fluorescence (42 s after
injection of 0.4 mg/kg MB) showing significant PG fluorescence (dotted
circle) compared to thyroid and surround soft tissues
Langenbecks Arch Surg
oncologic surgery. J Surg Oncol 104(3):323–332. https://doi.org/
10.1002/jso.21943
6. Crane LM, Themelis G, Arts HJ, Buddingh KT, Brouwers AH,
Ntziachristos V et al (2011) Intraoperative near-infrared fluores-
cence imaging for sentinel lymph node detection in vulvar cancer:
first clinical results. Gynecol Oncol 120(2):291–295. https://doi.
org/10.1016/j.ygyno.2010.10.009
7. Matsui A, Tanaka E, Choi HS, Kianzad V, Gioux S, Lomnes SJ,
Frangioni JV (2010) Real-time, near-infrared, fluorescence-guided
identification of the ureters using methylene blue. Surgery 148(1):
78–86. https://doi.org/10.1016/j.surg.2009.12.003
8. Matsui A, Tanaka E, Choi HS, Winer JH, Kianzad V, Gioux S,
Laurence RG, Frangioni JV (2010) Real-time intra-operative
near-infrared fluorescence identification of the extrahepatic bile
ducts using clinically available contrast agents. Surgery 148(1):
87–95. https://doi.org/10.1016/j.surg.2009.12.004
9. Tummers QR, Boonstra MC, Frangioni JV, van de Velde CJ,
Vahrmeijer AL, Bonsing BA (2015) Intraoperative near-infrared
fluorescence imaging of a paraganglioma using methylene blue: a
case report. Int J Surg Case Rep 6C:150–153. https://doi.org/10.
1016/j.ijscr.2014.12.002
10. van der Vorst JR, Schaafsma BE, Verbeek FP, Keereweer S, Jansen
JC, van der Velden LA et al (2013) Near-infrared fluorescence
sentinel lymph node mapping of the oral cavity in head and neck
cancer patients. Oral Oncol 49(1):15–19. https://doi.org/10.1016/j.
oraloncology.2012.07.017
11. Hutteman M, van der Vorst JR, Gaarenstroom KN, Peters AA,
Mieog JS, Schaafsma BE et al (2012) Optimization of near-
infrared fluorescent sentinel lymph nodemapping for vulvar cancer.
Am J Obstet Gynecol 206(1):89 e1–89 e5
12. van der Vorst JR, Schaafsma BE, Verbeek FP, Swijnenburg RJ,
Hutteman M, Liefers GJ et al (2013) Dose optimization for near-
infrared fluorescence sentinel lymph node mapping in patients with
melanoma. Br J Dermatol 168(1):93–98. https://doi.org/10.1111/
bjd.12059
13. Gotoh K, Yamada T, Ishikawa O, Takahashi H, Eguchi H, YanoM,
Ohigashi H, Tomita Y, Miyamoto Y, Imaoka S (2009) A novel
image-guided surgery of hepatocellular carcinoma by indocyanine
green fluorescence imaging navigation. J Surg Oncol 100(1):75–
79. https://doi.org/10.1002/jso.21272
14. Hutteman M, van der Vorst JR, Mieog JS, Bonsing BA, Hartgrink
HH, Kuppen PJ et al (2011) Near-infrared fluorescence imaging in
patients undergoing pancreaticoduodenectomy. Eur Surg Res 47(2):
90–97. https://doi.org/10.1159/000329411
15. Ishizawa T, Fukushima N, Shibahara J, Masuda K, Tamura S, Aoki
T, HasegawaK, Beck Y, FukayamaM, Kokudo N (2009) Real-time
identification of liver cancers by using indocyanine green fluores-
cent imaging. Cancer 115(11):2491–2504. https://doi.org/10.1002/
cncr.24291
16. Lim C, Vibert E, Azoulay D, Salloum C, Ishizawa T, Yoshioka R,
Mise Y, Sakamoto Y, Aoki T, Sugawara Y, Hasegawa K, Kokudo N
(2014) Indocyanine green fluorescence imaging in the surgical
management of liver cancers: current facts and future implications.
J Visc Surg 151(2):117–124. https://doi.org/10.1016/j.jviscsurg.
2013.11.003
17. Sakoda M, Ueno S, Iino S, Hiwatashi K, Minami K, Kawasaki Y,
Kurahara H, Mataki Y, Maemura K, Uenosono Y, Shinchi H,
Natsugoe S (2014) Anatomical laparoscopic hepatectomy for hepa-
tocellular carcinoma using indocyanine green fluorescence imag-
ing. J Laparoendosc Adv Surg Tech A 24(12):878–882. https://doi.
org/10.1089/lap.2014.0243
18. Hsu M, Gupta M, Su LM, Liao JC (2014) Intraoperative optical
imaging and tissue interrogation during urologic surgery. Curr Opin
U ro l 24 ( 1 ) : 6 6–74 . h t t p s : / / d o i . o r g / 10 . 1097 /MOU.
0000000000000010
19. Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJ,
Frangioni JV (2013) Image-guided cancer surgery using near-
infrared fluorescence. Nature reviews. Clin Oncol 10(9):507–518
20. Hurvitz RJ, Perzik SL,Morgenstern L (1968) In vivo staining of the
parathyroid glands. A clinical study. Arch Surg 97(5):722–726.
https://doi.org/10.1001/archsurg.1968.01340050062007
21. Dudley NE (1971) Methylene blue for rapid identification of the
parathyroids. Br Med J 3(5776):680–681. https://doi.org/10.1136/
bmj.3.5776.680
22. Patel HP, Chadwick DR, Harrison BJ, Balasubramanian SP (2012)
Systematic review of intravenous methylene blue in parathyroid
surgery. Br J Surg 99(10):1345–1351. https://doi.org/10.1002/bjs.
8814
23. Vutskits L, Briner A, Klauser P, Gascon E, Dayer AG, Kiss JZ,
Muller D, Licker MJ, Morel DR (2008) Adverse effects of methy-
lene blue on the central nervous system. Anesthesiology 108(4):
684–692. https://doi.org/10.1097/ALN.0b013e3181684be4
24. Antakia R, Gayet P, Guillermet S, Stephenson TJ, Brown NJ,
Harrison BJ, Balasubramanian SP (2014) Near infrared fluores-
cence imaging of rabbit thyroid and parathyroid glands. J Surg
Res 192(2):480–486. https://doi.org/10.1016/j.jss.2014.05.061
25. ClinicalTrials.gov (2012) Near Infrared Fluorescent Imaging in
Thyroid and Parathyroid Surgery With the Fluobeam(TM)
System of Fluoptics. Available from: https://clinicaltrials.gov/ct2/
show/NCT01598727?term=fluorescence+parathyroid&rank=2
26. Tummers QR, Schepers A, Hamming JF, Kievit J, Frangioni JV,
van de Velde CJ et al (2015) Intraoperative guidance in parathyroid
surgery using near-infrared fluorescence imaging and low-dose
methylene blue. Surgery 158(5):1323–1330. https://doi.org/10.
1016/j.surg.2015.03.027
27. van der Vorst JR, Schaafsma BE, Verbeek FP, Swijnenburg RJ,
Tummers QR, Hutteman M et al (2014) Intraoperative near-
infrared fluorescence imaging of parathyroid adenomas with use
of low-dose methylene blue. Head Neck 36(6):853–858. https://
doi.org/10.1002/hed.23384
28. Rasband WS (1997–2016) ImageJ Bethesda, Maryland, USA: U. S.
National Institutes of Health. Available from: http://imagej.nih.gov/ij/
29. ClinicalTrials.gov (2014) Intra-operative Infra-red Fluorescent
Imaging in Thyroid and Parathyroid Surgery. Available from:
https://clinicaltrials.gov/ct2/show/NCT02089542?term=
balasubramanian&rank=1
30. Sidi A, Paulus DA, Rush W, Gravenstein N, Davis RF (1987)
Methylene blue and indocyanine green artifactually lower pulse
oximetry readings of oxygen saturation. Studies in dogs. J Clin
Monit 3(4):249–256
31. Varon AJ, Anderson HB, Civetta JM (1989) Desaturation noted by
pulmonary artery catheter oximeter after methylene blue injection.
Anesthesiology 71(5):791–794. https://doi.org/10.1097/00000542-
198911000-00029
32. De Leeuw F, Breuskin I, Abbaci M, Casiraghi O, Mirghani H, Ben
Lakhdar A, Laplace-Builhé C, Hartl D (2016) Intraoperative near-
infrared imaging for parathyroid gland identification by auto-fluo-
rescence: a feasibility study.World J Surg 40(9):2131–2138. https://
doi.org/10.1007/s00268-016-3571-5
33. McWade MA, Paras C, White LM, Phay JE, Solorzano CC, Broome
JT et al (2014) Label-free intraoperative parathyroid localization with
near-infrared autofluorescence imaging. J Clin Endocrinol Metab
99(12):4574–4580. https://doi.org/10.1210/jc.2014-2503
34. Paras C, Keller M, White L, Phay J, Mahadevan-Jansen A (2011)
Near-infrared autofluorescence for the detection of parathyroid
glands. J Biomed Opt 16(6):067012. https://doi.org/10.1117/1.
3583571
35. McWadeMA, Paras C, White LM, Phay JE, Mahadevan-Jansen A,
Broome JT (2013) A novel optical approach to intraoperative de-
tection of parathyroid glands. Surgery 154(6):1371–1377; discus-
sion 7. https://doi.org/10.1016/j.surg.2013.06.046
Langenbecks Arch Surg
